Targeted Oncology10 小时
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
Compugen: Immuno-Oncology Innovator Poised For A Comeback
Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...
GlobalData on MSN15 小时
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Galderma's Nemluvio® (Nemolizumab) Granted Marketing Authorization In The United Kingdom ...
Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...
Armed robbery in Revesby21 小时
Galderma's Nemluvio Approved in UK, Switzerland
These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the ...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
CMAJ14 小时
Diagnosis and management of chronic rhinosinusitis
KEY POINTS Chronic rhinosinusitis refers to symptomatic inflammation of the nose and paranasal sinuses that has been present for a minimum of 3 months.[1][1] Its true prevalence is difficult to ...
Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) sBLA Accepted for FDA Priority Review ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...